BIGBEAR
PHARMACEUTICAL
Sotorasib covalently binds to the switch pocket of KRAS G12C mutant protein, specifically inhibits GTPase activity and blocks abnormal RAS signaling.
AuthenticGuaranteeFast DeliveryPrivacy Sotorasib is an oral targeted cancer therapy drug that received U.S. FDA approval in May 2021 (marketed under the brand name Lumakras). It is indicate···【More】
Update: 27 Apr,2026Source: BigbearViews: 74
KRAS mutations have been considered a major challenge in cancer research, remaining difficult to overcome for many years. The introduction of Sotorasi···【More】
Update: 04 Mar,2026Source: BigbearViews: 90
Sotorasib is a KRASG12C inhibitor developed by Amgen. It received accelerated approval from the U.S. Food and Drug Administration (FDA) in May 2021.I.···【More】
Update: 03 Mar,2026Source: BigbearViews: 90
In 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sotorasib for the treatment of certain adult patients with non-sm···【More】
Update: 03 Mar,2026Source: BigbearViews: 96
Sotorasib is an oral targeted anticancer drug developed by Amgen, a small molecule inhibitor specifically targeting the KRAS G12C mutation.Indications···【More】
Update: 03 Mar,2026Source: BigbearViews: 96
Sotorasib is a targeted drug against KRASG12C mutations, primarily used to treat malignant tumors such as non-small cell lung cancer. Common side effe···【More】
Update: 27 Feb,2026Source: BigbearViews: 96
While taking sottorazib, it is generally not recommended to consume large amounts of fatty foods. However, small or occasional intake is usually harml···【More】
Update: 27 Feb,2026Source: BigbearViews: 91
The usual recommended dose of sotorasib is 960 mg (8 tablets x 120 mg) once daily, taken on an empty stomach at least 1 hour before or 2 hours after e···【More】
Update: 25 Feb,2026Source: BigbearViews: 95
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
